Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 177

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 177
---
angible Assets and Rights of Use
In 2024, we continued advancing our capital investment plan to expand and improve the production facilities of our business units. We believe we have significantly optimized our capital expenditures resource allocations considering the investments already made in recent years. In 2024, our capital expenditures totaled €261.3 million (€281.5 million in 2023). The following table presents our capital expenditures, other intangible assets and rights of use additions in the years ended December 31, 2024, 2023 and 2022, by business unit.

     ​         ​       ​       ​        ​       ​        ​   
-------------------------------------------------------------
​              ​                      Year Ended December 31,
​              2024                  2023(1)          2022(1)
​              ​                      (in thousands of euros)
Biopharma           373,380          359,442          507,457
Diagnostic           54,575           29,107           49,890
Bio Supplies          2,128            9,066   98            
Others                7,619            3,884           30,192
Unallocated          40,488           48,618           59,866
Total               478,190          450,117          647,503

(1)   The financial information as of and for the years ended December 31, 2023 and 2022 has been restated to apply changes in criteria and correct errors. See “Factors Affecting Our Financial Condition and Results of Operations—Changes in accounting criteria and correction of errors” above and see Notes 2(d) and 10 to our consolidated financial statements as of and for the year ended December 31, 2024, included in this annual report on Form 20-F.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
January 2022 through December 2024
Facilities. The most important capital projects relating to the expansion and improvement of our manufacturing facilities during 2024, 2023 and 2022 were:
Parets site (Barcelona, Spain):

●   investments to increase purification capacity of fibrin sealant and topic thrombin of €0.2 million in 2024, €0.1 million in 2023 and €3.7 million in 2022;
--------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments to increase the production of intravenous solutions bags of €1.3 million in 202